pipeline

Product pipeline

Clinical

Discovery

Pipeline Code

Target

Modality

Indication

IND-Enabling

Phase I

Phase II

Phase III

Partners

RP901

General

Small Molecule

RP901 is a small molecule innovative drug discovered and developed by Risen. After oral administration, RP901 can be rapidly transformed in vivo to protect bone and improve the symptoms of osteoarthritis, and is used for the treatment of osteoarthritis (OA). OA is a degenerative disease with joint pain as the main symptom caused by multiple factors such as joint cartilage fibrosis, chapping, ulcer and loss.

RP901

preclinical

IND

Phase I

Phase II

Phase III

Target :General

Modality :Small Molecule

Indication :OA

Partners:

RP902

Amyloid-β

Small Molecule

Alzheimer's Disease （AD）

RP902 is A stable isotope substituted small molecule innovative drug discovered and developed by Risen, which takes β-Amyloid (Aβ) as the main target for the treatment of Alzheimer's disease (AD).

RP902

preclinical

IND

Phase I

Phase II

Phase III

Target :Amyloid-β

Modality :Small Molecule

Indication :Alzheimer's Disease （AD）

Partners:

RP902 is A stable isotope substituted small molecule innovative drug discovered and developed by Risen, which takes β-Amyloid (Aβ) as the main target for the treatment of Alzheimer's disease (AD).

RP903

PI3Kα

Small Molecule

Cancer & PROS

RP903 is a stable isotope replacement small molecule innovative drug discovered and developed by Risen. It is a selective small molecule inhibitor targeting PI3Kα, which is used for the treatment of advanced malignant solid tumors with PIK3CA mutation.

RP903

preclinical

IND

Phase I

Phase II

Phase III

Target :PI3Kα

Modality :Small Molecule

Indication :Cancer & PROS

Partners:

RP916

DNA Polymerase

Small Molecule

monkeypox virus infection

RP916 is a nucleoside antiviral drug jointly developed by Risen Pharma and the Shanghai Center for Infectious and Immunological Diseases Innovation. After oral administration, it can be converted into an active component in the body, which inhibits the viral DNA polymerase and blocks the replication process of the virus. It is intended for the treatment of orthopoxvirus (especially monkeypox virus) infections.

RP916

preclinical

IND

Phase I

Phase II

Phase III

Target :DNA Polymerase

Modality :Small Molecule

Indication :monkeypox virus infection

Partners:

Pipeline Code

Target

Modality

Indication

Lead ID

Lead Optimization

PCC

IND-Enabling

Partners

RJ008

undisclosed

small molecule

cancer

RJ008

Lead ID

Lead Optimization

PCC

IND-Enabling

Target :undisclosed

Modality :small molecule

Indication :cancer

Partners:

RJ027

undisclosed

siRNA

Alzheimer's disease

RJ027

Lead ID

Lead Optimization

PCC

IND-Enabling

Target :undisclosed

Modality :siRNA

Indication :Alzheimer's disease

Partners:

RJ029

Dual-Target (undisclosed)

siRNA

Metabolic diseases

RJ029

Lead ID

Lead Optimization

PCC

IND-Enabling

Target :Dual-Target (undisclosed)

Modality :siRNA

Indication :Metabolic diseases

Partners:

RJ031

Dual-Target (undisclosed)

siRNA

Alzheimer's disease

RJ031

Lead ID

Lead Optimization

PCC

IND-Enabling

Target :Dual-Target (undisclosed)

Modality :siRNA

Indication :Alzheimer's disease

Partners:

RJ032

undisclosed

AOC

Alzheimer's disease

RJ032

Lead ID

Lead Optimization

PCC

IND-Enabling

Target :undisclosed

Modality :AOC

Indication :Alzheimer's disease

Partners: